Pharmaceuticals company Morepen Laboratories announced Q2FY25 results Financial Highlights: Net Revenue: Rs 425.00 crore compared to Rs 442.71 crore during Q2FY24, change 4%. EBITDA: Rs 36.83 crore compared to Rs 49.06 crore during Q2FY24, change 33%. EBITDA margin: 8.66% for Q2FY25. PBT: Rs 28.68 crore compared to Rs 46.02 crore during Q2FY24, change 60%. PAT: Rs 21.26 crore compared to Rs 34.85 crore during Q2FY24, change 64%. PAT margin: 5% for Q2FY25. Earnings Per Share: Rs 0.42 for Q2FY25. Sushil Suri, Chairman and Managing Director, Morepen Laboratories, said: “At Morepen, we are all supercharged to execute our strategic mission, ‘Morepen 2.0,’ as we target Rs 5000 crore (5K) in revenue by 2030. We are dedicated to building on our strengths across both domestic and global markets. As we pivot our forthcoming investments towards Medical Devices and Consumer Health, we remain committed to innovation and research in our core API business. We will continue to invest in technology and improve our operational efficiencies. The company continues to remain debt free and we will leverage our cash position to improve our product pipeline.” “We are extremely confident of our growth strategies for achieving our long-term strategic goals. Our Focus remains on developing innovative products, tap newer markets including exports and improve profitability further. With our recent fundraise via the QIP route placing us at the forefront of marquee investors, we are actively evaluating various options to fund our growth plans on our journey to the 5K milestone.“ Result PDF